5-Year Results With a Retinal Prosthesis System

Patients with severe to profound RP are experiencing promising outcomes wit…

Read Article


Visit @RetinaToday on Twitter

Articles From This Issue


Innovations in Retinaland

Medical Editors’ Page

A great man once said, “The world as we have created it is a process of our thinking. It cannot be changed without changing our thinking.” Albert Einstein was …

Retina News

Combination Therapy Shows No Benefit Over Aflibercept Alone in Phase 2 AMD Trial The phase 2 CAPELLA study evaluating aflibercept (Eylea, Regeneron) coformulated with rinuc…

  • AMD Awareness Month
  • DME Disease Education Resource Center
  • Uveitis Resource Center
  • ZEISS OCT Angiography eNewsletter Series
  • AMD Disease Education Resource Center
  • NEWS


    Spark Therapeutics Launches Initiative to Improve Access to Genetic Testing for Inherited Retinal Diseases

    Spark Therapeutics will provide physicians and eligible patients access to genetic testing and couns…

    Lucentis Recommended by CHMP for EU Approval in Sixth Indication for the Treatment of Visually Impaired Patients

    Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a posi…

    Video Series

    Contact Info

    Bryn Mawr Communications LLC
    1008 Upper Gulph Road, Suite 200
    Wayne, PA 19087

    Phone: 484-581-1800
    Fax: 484-581-1818

    Karen Roman

    Janet Burk

    About Retina Today

    Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.